The estimated Net Worth of Mohammad Azab is at least $2.87 millió dollars as of 19 December 2023. Mohammad Azab owns over 4,320 units of Xenon Pharmaceuticals Inc stock worth over $2,868,796 and over the last 10 years he sold XENE stock worth over $214. In addition, he makes $0 as Independent Director at Xenon Pharmaceuticals Inc.
Sign up
Mohammad Azab XENE stock SEC Form 4 insiders trading
Mohammad has made over 16 trades of the Xenon Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 4,320 units of XENE stock worth $42,552 on 19 December 2023.
The largest trade he's ever made was buying 30,000 units of Xenon Pharmaceuticals Inc stock on 24 May 2022 worth over $11,700. On average, Mohammad trades about 4,623 units every 109 days since 2014. As of 19 December 2023 he still owns at least 74,225 units of Xenon Pharmaceuticals Inc stock.
You can see the complete history of Mohammad Azab stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mohammad Azab biography
Dr. Mohammad Azab serves as Independent Director of the Company. Dr. Azab joined Astex Pharmaceuticals, Inc., a pharmaceutical company focused on the discovery and development of drugs in oncology and other areas, as its Chief Medical Officer. Since January 2014, Dr. Azab has served as President and Chief Medical Officer of Astex and has been a member of Astex’s Board of Directors. Previously, Dr. Azab served as President and CEO of Intradigm Corporation, a developer of siRNA cancer therapeutics. Prior to this, Dr. Azab served as Executive Vice President of Research and Development, and Chief Medical Officer of QLT Inc., and in several leadership positions at Astra Zeneca in the United Kingdom and Sanofi Pharmaceuticals in France. Dr. Azab holds an M.B.A. from the Richard Ivey School of Business, University of Western Ontario, and an MB ChB from Cairo University. He received post-graduate training and degrees in oncology research from the University of Paris-Sud and biostatistics from the University of Pierre et Marie Curie in Paris, France. Our Board believes Dr. Azab is qualified to serve on our Board because of his scientific background and his senior management experience in the pharmaceutical industry.
How old is Mohammad Azab?
Mohammad Azab is 64, he's been the Independent Director of Xenon Pharmaceuticals Inc since 2003. There are 3 older and 19 younger executives at Xenon Pharmaceuticals Inc. The oldest executive at Xenon Pharmaceuticals Inc is Michael Tarnow, 74, who is the Independent Chairman of the Board.
What's Mohammad Azab's mailing address?
Mohammad's mailing address filed with the SEC is 200 - 3650 GILMORE WAY, , BURNABY, A1, V5G 4W8.
Insiders trading at Xenon Pharmaceuticals Inc
Over the last 10 years, insiders at Xenon Pharmaceuticals Inc have traded over $12,977,011 worth of Xenon Pharmaceuticals Inc stock and bought 724,015 units worth $2,649,316 . The most active insiders traders include Patrick Machado, Partners L P/Ilbiotechnolog... és Justin D. Gover. On average, Xenon Pharmaceuticals Inc executives and independent directors trade stock every 31 days with the average trade being worth of $818,878. The most recent stock trade was executed by Elizabeth A. Garofalo on 8 March 2024, trading 3,500 units of XENE stock currently worth $64,960.
What does Xenon Pharmaceuticals Inc do?
xenon® (nasdaq: xene) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as extreme genetics. our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. we apply our expertise to predict which phenotypes are caused by single-gene defects. by identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.
What does Xenon Pharmaceuticals Inc's logo look like?
Complete history of Mohammad Azab stock trades at Durect Corp és Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc executives and stock owners
Xenon Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Simon Pimstone,
Chief Executive Officer, Director -
Ian Mortimer,
President, Chief Financial Officer, Corporate Secretary -
Ernesto Aycardi-Fonseca,
Chief Medical Officer -
Dr. Simon N. Pimstone FRCPC, M.B. ChB., M.D., Ph.D.,
Exec. Chairman -
Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA,
Pres, CEO & Director -
Robin Sherrington,
Executive Vice President - Strategy & Innovation -
James Empfield,
Senior Vice President - Drug Discovery -
Dr. Christopher John Kenney M.D.,
Chief Medical Officer -
Michael Tarnow,
Independent Chairman of the Board -
Dawn Svoronos,
Independent Director -
Gary Patou,
Independent Director -
Frank Holler,
Independent Director -
Michael Hayden,
Independent Director -
Steven Gannon,
Independent Director -
Clarissa Desjardins,
Independent Director -
Mohammad Azab,
Independent Director -
Shelley McCloskey,
Senior Vice President - Human Resources -
Dr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D.,
Chief Commercial Officer -
Dr. Kenneth Sommerville,
Interim Chief Medical Officer -
Dr. Christopher E. Von Seggern M.B.A., M.P.H., Ph.D., M.P.H. M.B.A,
Chief Commercial Officer -
Sheila M. Grant M.B.A., M.Sc., MBA,
Sr. VP of R&D Operations -
Dr. James R. Empfield,
Exec. VP of Drug Discovery -
Dr. Robin P. Sherrington,
Exec. VP of Strategy & Innovation -
Shelley McCloskey B.A.,
Sr. VP of HR -
Jodi Regts M.B.A., B.A., MBA,
VP of Corp. Affairs & Investor Relations -
Sherry Aulin,
Chief Financial Officer -
Charles J. Cohen,
VP, Biology -
Raymond Winquist,
Head, Translational Research -
Partners L P/Ilbiotechnolog...,
-
Richard H Scheller,
Director -
Christopher John Kenney,
Chief Medical Officer -
Sherry Aulin,
Chief Financial Officer -
Seggern Christopher Von,
Chief Commercial Officer -
Elizabeth A. Garofalo,
-
Patrick Machado,
-
Y. Paul Goldberg,
VP, Clinical Development -
Associates, Llp Mx,
10% owner -
Karen G. Corraini,
Gen. Counsel & Corp. Secretary -
Johnston L Evans,
Director -
Evan A. Stein,
Director -
Gary Bridger,
EVP, Research & Development -
Gillian Cannon,
-
Justin D. Gover,